Biblioteca Humberto Rosselli Quijano
|
Ejemplares (1)
| Código de barras | Signatura | Tipo de medio | Ubicación | Sección | Estado |
|---|---|---|---|---|---|
| 101508 | psychiatric clinics of North America | Publicaciones seriadas | Biblioteca Instituto Colombiano del Sistema Nervioso | Hemeroteca | Disponible |
Artículos
Añadir el resultado a su cestaDoes biology transcend the symptom-based boundaries of psychosis? / Godfrey D Pearlson en Psychiatric Clinics of North America, Año 2016 - Vol.39 - No.2 (Junio)
Título : Does biology transcend the symptom-based boundaries of psychosis? Tipo de documento: texto impreso Autores: Godfrey D Pearlson, Autor ; Brett A Clementz, Autor ; John A Sweeney, Autor Fecha de publicación: 2020 Artículo en la página: pp. 165-174 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Psicosis, Biotipo, Neurobiología, Reclasificación, Esquizofrenia, Esquizoafectivo Bipolar Resumen: Psychotic disorders, as defined by clinical features alone, overlap considerably in terms of symptoms, familial patterns, risk genes, outcome, and treatment response. As a result, numerous neurobiological measurements fail to distinguish patients with the most prevalent classic psychotic syndromes. Link: ./index.php?lvl=notice_display&id=24122
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 165-174[artículo] Does biology transcend the symptom-based boundaries of psychosis? [texto impreso] / Godfrey D Pearlson, Autor ; Brett A Clementz, Autor ; John A Sweeney, Autor . - 2020 . - pp. 165-174.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 165-174
Palabras clave: Psicosis, Biotipo, Neurobiología, Reclasificación, Esquizofrenia, Esquizoafectivo Bipolar Resumen: Psychotic disorders, as defined by clinical features alone, overlap considerably in terms of symptoms, familial patterns, risk genes, outcome, and treatment response. As a result, numerous neurobiological measurements fail to distinguish patients with the most prevalent classic psychotic syndromes. Link: ./index.php?lvl=notice_display&id=24122
Título : Are we really impacting duration of untreated psychosis and does It matter? : longitudinal perspectives on early intervention from the Irish public health services Tipo de documento: texto impreso Autores: Mary Clarke, Autor ; Catherine M McDonough, Autor ; Roisin Doyle, Autor Fecha de publicación: 2020 Artículo en la página: pp. 175-186 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Duración de la psicosis no tratada, Salir, Intervención rápida, Fase prodrómica, Servicio de salud pública Resumen: Although early intervention in psychosis is clinically intuitive and theoretically feasible, the reality is that over recent decades the evidence base to support it has not advanced as much as might have been anticipated. Material benefits of early intervention in established psychosis have not been universally demonstrated and much uncertainty continues to surround the field of treatment in the prodromal phase. Link: ./index.php?lvl=notice_display&id=24123
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 175-186[artículo] Are we really impacting duration of untreated psychosis and does It matter? : longitudinal perspectives on early intervention from the Irish public health services [texto impreso] / Mary Clarke, Autor ; Catherine M McDonough, Autor ; Roisin Doyle, Autor . - 2020 . - pp. 175-186.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 175-186
Palabras clave: Duración de la psicosis no tratada, Salir, Intervención rápida, Fase prodrómica, Servicio de salud pública Resumen: Although early intervention in psychosis is clinically intuitive and theoretically feasible, the reality is that over recent decades the evidence base to support it has not advanced as much as might have been anticipated. Material benefits of early intervention in established psychosis have not been universally demonstrated and much uncertainty continues to surround the field of treatment in the prodromal phase. Link: ./index.php?lvl=notice_display&id=24123
Título : The case for adjunctive monoclonal antibody immunotherapy in schizophrenia Tipo de documento: texto impreso Autores: Brian J. Miller, Autor ; Peter F Buckley, Autor Fecha de publicación: 2020 Artículo en la página: pp. 187-198 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Esquizofrenia, Psicosis, Inmune, Inflamación, Citocina, Anticuerpo monoclonal, Tratamiento, Adjunto Resumen: This article presents the case in favor of clinical trials of adjunctive monoclonal antibody immunotherapy in schizophrenia. Evidence for prenatal and premorbid immune risk factors for the development of schizophrenia in the offspring is highlighted. Link: ./index.php?lvl=notice_display&id=24124
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 187-198[artículo] The case for adjunctive monoclonal antibody immunotherapy in schizophrenia [texto impreso] / Brian J. Miller, Autor ; Peter F Buckley, Autor . - 2020 . - pp. 187-198.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 187-198
Palabras clave: Esquizofrenia, Psicosis, Inmune, Inflamación, Citocina, Anticuerpo monoclonal, Tratamiento, Adjunto Resumen: This article presents the case in favor of clinical trials of adjunctive monoclonal antibody immunotherapy in schizophrenia. Evidence for prenatal and premorbid immune risk factors for the development of schizophrenia in the offspring is highlighted. Link: ./index.php?lvl=notice_display&id=24124
Título : Redefining medication adherence in the treatment of schizophrenia : how current approaches to adherence lead to misinformation and threaten therapeutic relationships Tipo de documento: texto impreso Autores: Peter J. Weiden, Autor Fecha de publicación: 2020 Artículo en la página: pp. 199-216 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Resultados de la esquizofrenia, Aceptación de la atención sanitaria por parte del paciente, Recaída, Relaciones médico-paciente, Reducción de daños Comunicación Resumen: Medication adherence is as much of a problem today as it was 50 years ago. A major barrier to progress is that the definition emphasizes obedience to medication recommendations rather than shared outcome goals. As a result, schizophrenia patients are keenly aware of the social risks of disclosing nonadherence. Link: ./index.php?lvl=notice_display&id=24125
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 199-216[artículo] Redefining medication adherence in the treatment of schizophrenia : how current approaches to adherence lead to misinformation and threaten therapeutic relationships [texto impreso] / Peter J. Weiden, Autor . - 2020 . - pp. 199-216.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 199-216
Palabras clave: Resultados de la esquizofrenia, Aceptación de la atención sanitaria por parte del paciente, Recaída, Relaciones médico-paciente, Reducción de daños Comunicación Resumen: Medication adherence is as much of a problem today as it was 50 years ago. A major barrier to progress is that the definition emphasizes obedience to medication recommendations rather than shared outcome goals. As a result, schizophrenia patients are keenly aware of the social risks of disclosing nonadherence. Link: ./index.php?lvl=notice_display&id=24125
Título : Update on new and emerging treatments for schizophrenia Tipo de documento: texto impreso Autores: Ganesh Gopalakrishna, Autor ; Muaid H. Ithman, Autor ; John Lauriello, Autor Fecha de publicación: 2020 Artículo en la página: pp. 217-238 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Esquizofrenia, Avances, Antipsicóticos, Conocimiento, Síntomas negativos Resumen: Although there has been more than 50 years of development, there remains a great need for better antipsychotic medications. This article looks at the recent advances in treatment of schizophrenia. New hypotheses have been suggested that may replace or complement the dopamine hypotheses. Link: ./index.php?lvl=notice_display&id=24126
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 217-238[artículo] Update on new and emerging treatments for schizophrenia [texto impreso] / Ganesh Gopalakrishna, Autor ; Muaid H. Ithman, Autor ; John Lauriello, Autor . - 2020 . - pp. 217-238.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 217-238
Palabras clave: Esquizofrenia, Avances, Antipsicóticos, Conocimiento, Síntomas negativos Resumen: Although there has been more than 50 years of development, there remains a great need for better antipsychotic medications. This article looks at the recent advances in treatment of schizophrenia. New hypotheses have been suggested that may replace or complement the dopamine hypotheses. Link: ./index.php?lvl=notice_display&id=24126
Título : Treatment-resistant schizophrenia Tipo de documento: texto impreso Autores: Helio Elkis, Autor ; Peter F Buckley, Autor Fecha de publicación: 2020 Artículo en la página: pp. 239-265 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Esquizofrenia, Tratamiento, Resistencia Resumen: Although treatment-resistant schizophrenia (TRS) was described 50 years ago and has a gold standard treatment with clozapine based on well-defined criteria, there is still a matter of great interest and controversy. In terms of the underlying mechanisms of the development of TRS, progress has been made for the elucidation of the neurochemical mechanisms. Link: ./index.php?lvl=notice_display&id=24127
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 239-265[artículo] Treatment-resistant schizophrenia [texto impreso] / Helio Elkis, Autor ; Peter F Buckley, Autor . - 2020 . - pp. 239-265.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 239-265
Palabras clave: Esquizofrenia, Tratamiento, Resistencia Resumen: Although treatment-resistant schizophrenia (TRS) was described 50 years ago and has a gold standard treatment with clozapine based on well-defined criteria, there is still a matter of great interest and controversy. In terms of the underlying mechanisms of the development of TRS, progress has been made for the elucidation of the neurochemical mechanisms. Link: ./index.php?lvl=notice_display&id=24127
Título : Transcending psychosis : the complexity of comorbidity in schizophrenia Tipo de documento: texto impreso Autores: Sun Young Yum, Autor ; Michael Y. Hwang, Autor ; Henry A. Nasrallah, Autor Fecha de publicación: 2020 Artículo en la página: pp. 267-274 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Esquizofrenia, Trastorno comórbido, Patogenia, Diagnóstico, Tratamiento Resumen: Schizophrenic illness encompasses diverse clinical phenomena and consists of unclear underlying pathogeneses. For the past century, the comorbidities in schizophrenia have drawn persistent interest and debate due to its high prevalence rate and a need for better management. However, its clinical and biological diversity continue to challenge both the practicing clinicians and researchers. Link: ./index.php?lvl=notice_display&id=24128
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 267-274[artículo] Transcending psychosis : the complexity of comorbidity in schizophrenia [texto impreso] / Sun Young Yum, Autor ; Michael Y. Hwang, Autor ; Henry A. Nasrallah, Autor . - 2020 . - pp. 267-274.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 267-274
Palabras clave: Esquizofrenia, Trastorno comórbido, Patogenia, Diagnóstico, Tratamiento Resumen: Schizophrenic illness encompasses diverse clinical phenomena and consists of unclear underlying pathogeneses. For the past century, the comorbidities in schizophrenia have drawn persistent interest and debate due to its high prevalence rate and a need for better management. However, its clinical and biological diversity continue to challenge both the practicing clinicians and researchers. Link: ./index.php?lvl=notice_display&id=24128
Título : Detecting and managing adverse effects of antipsychotic medications : current state of play Tipo de documento: texto impreso Autores: Donna Ames, Autor ; Sian M. Carr-Lopez, Autor ; Mary A Gutierrez, Autor Fecha de publicación: 2020 Artículo en la página: pp. 275-311 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Medicación antipsicótica, Efectos adversos, Antipsicóticos de primera generación, Antipsicóticos de segunda generación, Aumento de peso, Hiperlipidemia Prolongación del intervalo QT, Hiperprolactinemia Resumen: Antipsychotics are some of the most frequently prescribed medications not only for psychotic disorders and symptoms but also for a wide range of on-label and off-label indications. Because second-generation antipsychotics have largely replaced first-generation antipsychotics as first-line options due to their substantially decreased risk of extrapyramidal side effects,... Link: ./index.php?lvl=notice_display&id=24129
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 275-311[artículo] Detecting and managing adverse effects of antipsychotic medications : current state of play [texto impreso] / Donna Ames, Autor ; Sian M. Carr-Lopez, Autor ; Mary A Gutierrez, Autor . - 2020 . - pp. 275-311.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 275-311
Palabras clave: Medicación antipsicótica, Efectos adversos, Antipsicóticos de primera generación, Antipsicóticos de segunda generación, Aumento de peso, Hiperlipidemia Prolongación del intervalo QT, Hiperprolactinemia Resumen: Antipsychotics are some of the most frequently prescribed medications not only for psychotic disorders and symptoms but also for a wide range of on-label and off-label indications. Because second-generation antipsychotics have largely replaced first-generation antipsychotics as first-line options due to their substantially decreased risk of extrapyramidal side effects,... Link: ./index.php?lvl=notice_display&id=24129
Título : Recovery in schizophrenia : what consumers know and do not know Tipo de documento: texto impreso Autores: Anthony O. Ahmed, Autor ; Brielle A. Marino, Autor Fecha de publicación: 2020 Artículo en la página: pp. 313-330 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Modelo de recuperación, Apoyo entre pares, Autogestión de enfermedades, Vivienda con apoyo, Empleo con apoyo, Modelo de fortalezas, Toma de decisiones compartida, Directivas anticipadas Resumen: The recovery model has permeated mental health systems by leading to the development of new psychiatric interventions and services and the reconfiguration of traditional ones. There is growing evidence that these interventions and services confer benefits in clinical and recovery-oriented outcomes. Link: ./index.php?lvl=notice_display&id=24130
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 313-330[artículo] Recovery in schizophrenia : what consumers know and do not know [texto impreso] / Anthony O. Ahmed, Autor ; Brielle A. Marino, Autor . - 2020 . - pp. 313-330.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 313-330
Palabras clave: Modelo de recuperación, Apoyo entre pares, Autogestión de enfermedades, Vivienda con apoyo, Empleo con apoyo, Modelo de fortalezas, Toma de decisiones compartida, Directivas anticipadas Resumen: The recovery model has permeated mental health systems by leading to the development of new psychiatric interventions and services and the reconfiguration of traditional ones. There is growing evidence that these interventions and services confer benefits in clinical and recovery-oriented outcomes. Link: ./index.php?lvl=notice_display&id=24130
Título : What does mental health parity really mean for the care of people with serious mental illness? Tipo de documento: texto impreso Autores: John Bartlett, Autor ; Ron Manderscheid, Autor Fecha de publicación: 2020 Artículo en la página: pp. 331-342 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Paridad, Asequible, Ley de atención médica, MHPAEA, Ley, población con SMI, Beneficios de salud mental y abuso de sustancias, Beneficios de salud esenciales, Expansión de Medicaid, Limitaciones de tratamiento no cuantitativas Resumen: Parity of mental health and substance abuse insurance benefits with medical care benefits, as well as parity in their management, are major ongoing concerns for adults with serious mental illness (SMI). The Mental Health Parity and Addiction Equity Act of 2008 guaranteed this parity of benefits and management in large private insurance plans and privately managed state Medicaid plans, but only if the benefits were offered at all. Link: ./index.php?lvl=notice_display&id=24131
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 331-342[artículo] What does mental health parity really mean for the care of people with serious mental illness? [texto impreso] / John Bartlett, Autor ; Ron Manderscheid, Autor . - 2020 . - pp. 331-342.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 331-342
Palabras clave: Paridad, Asequible, Ley de atención médica, MHPAEA, Ley, población con SMI, Beneficios de salud mental y abuso de sustancias, Beneficios de salud esenciales, Expansión de Medicaid, Limitaciones de tratamiento no cuantitativas Resumen: Parity of mental health and substance abuse insurance benefits with medical care benefits, as well as parity in their management, are major ongoing concerns for adults with serious mental illness (SMI). The Mental Health Parity and Addiction Equity Act of 2008 guaranteed this parity of benefits and management in large private insurance plans and privately managed state Medicaid plans, but only if the benefits were offered at all. Link: ./index.php?lvl=notice_display&id=24131
Título : What does mental health parity really mean for the care of people with serious mental illness? Tipo de documento: texto impreso Autores: John Bartlett, Autor ; Ron Manderscheid, Autor Fecha de publicación: 2020 Artículo en la página: pp. 331-342 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Paridad, Asequible, Ley de atención médica, MHPAEA, Ley, población con SMI, Beneficios de salud mental y abuso de sustancias, Beneficios de salud esenciales, Expansión de Medicaid, Limitaciones de tratamiento no cuantitativas Resumen: Parity of mental health and substance abuse insurance benefits with medical care benefits, as well as parity in their management, are major ongoing concerns for adults with serious mental illness (SMI). The Mental Health Parity and Addiction Equity Act of 2008 guaranteed this parity of benefits and management in large private insurance plans and privately managed state Medicaid plans, but only if the benefits were offered at all. Link: ./index.php?lvl=notice_display&id=24132
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 331-342[artículo] What does mental health parity really mean for the care of people with serious mental illness? [texto impreso] / John Bartlett, Autor ; Ron Manderscheid, Autor . - 2020 . - pp. 331-342.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 331-342
Palabras clave: Paridad, Asequible, Ley de atención médica, MHPAEA, Ley, población con SMI, Beneficios de salud mental y abuso de sustancias, Beneficios de salud esenciales, Expansión de Medicaid, Limitaciones de tratamiento no cuantitativas Resumen: Parity of mental health and substance abuse insurance benefits with medical care benefits, as well as parity in their management, are major ongoing concerns for adults with serious mental illness (SMI). The Mental Health Parity and Addiction Equity Act of 2008 guaranteed this parity of benefits and management in large private insurance plans and privately managed state Medicaid plans, but only if the benefits were offered at all. Link: ./index.php?lvl=notice_display&id=24132
Título : What’s hot in schizophrenia research? Tipo de documento: texto impreso Autores: Cynthia Shannon Weickert, Autor ; Thomas W. Weickert, Autor Fecha de publicación: 2020 Artículo en la página: pp. 343-351 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Esquizofrenia, Psicosis, Inflamación, Biomarcadores, Citocinas, Riesgo ultra alto, Microglía Resumen: Schizophrenia is a heterogeneous psychiatric illness for which the cause or causes are presently unknown. There is increasing evidence from multiple levels of research suggesting that inflammation may play an important role in the development and persistence of psychosis and cognitive impairment in a proportion of people with schizophrenia. Link: ./index.php?lvl=notice_display&id=24133
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 343-351[artículo] What’s hot in schizophrenia research? [texto impreso] / Cynthia Shannon Weickert, Autor ; Thomas W. Weickert, Autor . - 2020 . - pp. 343-351.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.2 (Junio) . - pp. 343-351
Palabras clave: Esquizofrenia, Psicosis, Inflamación, Biomarcadores, Citocinas, Riesgo ultra alto, Microglía Resumen: Schizophrenia is a heterogeneous psychiatric illness for which the cause or causes are presently unknown. There is increasing evidence from multiple levels of research suggesting that inflammation may play an important role in the development and persistence of psychosis and cognitive impairment in a proportion of people with schizophrenia. Link: ./index.php?lvl=notice_display&id=24133
